comparemela.com
Home
Live Updates
Primary Biliary - Breaking News
Pages:
11
12
13
14
15
16
17
Page 10 - Primary Biliary News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
United states
Jonathan silverberg
Christopher posner
Vifor pharma
Iris francesconi
Annie spinetta
Joana goncalves
Notalgia paresthetica
Brian kim
European academy of dermatology
American academy of dermatology annual meeting
Vifor fresenius medical care renal pharma ltd
Chong kun dang pharmaceutical corp
Pnational kidney foundation spring clinical meeting
Cara therapeutics inc
Kissei pharmaceutical co ltd
Crohn s disease (CD) Market Outlook, Epidemiology, Competitive Landscape & Market Forecast Report
Crohn’s disease (CD) Market Outlook, Epidemiology, Competitive Landscape & Market Forecast Report – 2020 to 2030
United states
Landos biopharma
Theravance biopharma
Reistone biopharma
Martina berg
Eli lilly
Provention bio
Insight report company
Gilead sciences
Elan pharmaceuticals
Boehringer ingelheim
See campaign
Research newswire
Valeant pharmaceuticals
Fast forward
Gaucher disease
Crohn s disease (CD) Market Outlook, Epidemiology, Competitive Landscape & Market Forecast Report
Crohn’s disease (CD) Market Outlook, Epidemiology, Competitive Landscape & Market Forecast Report – 2020 to 2030
United states
Landos biopharma
Theravance biopharma
Reistone biopharma
Martina berg
Eli lilly
Provention bio
Insight report company
Gilead sciences
Elan pharmaceuticals
Boehringer ingelheim
See campaign
Research newswire
Valeant pharmaceuticals
Fast forward
Gaucher disease
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
/PRNewswire/ COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced.
Northwestern university
United states
John puisis
Julie ferguson
Stephend miller
Ironwood pharmaceuticals inc
Drug administration
Judye guggenheim research professor of microbiology
Fast track designation
Primary biliary
Track designation
Accelerated approval
Ironwood pharmaceuticals
Research professor
Cour pharmaceuticals
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
/PRNewswire/ COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced.
Northwestern university
United states
John puisis
Julie ferguson
Stephend miller
Ironwood pharmaceuticals inc
Drug administration
Judye guggenheim research professor of microbiology
Fast track designation
Primary biliary
Track designation
Accelerated approval
Ironwood pharmaceuticals
Research professor
Cour pharmaceuticals
vimarsana © 2020. All Rights Reserved.